Back to Search Start Over

Glucocerebroside Ameliorates the Metabolic Syndrome in OB/OB Mice.

Authors :
Margalit, Maya
Shalev, Zvi
Pappo, Orit
Sklair-Levy, Miriam
Alper, Ruslana
Gomori, Moshe
Engelhardt, Dean
Rabbani, Elazar
Ilan, Yaron
Source :
The Journal of Pharmacology and Experimental Therapeutics; October 2006, Vol. 319 Issue: 1 p105-110, 6p
Publication Year :
2006

Abstract

Glucocerebroside (GC) is a naturally occurring glycolipid that may alter natural killer T (NKT) cell function. To determine the effect of GC on the metabolic derangements and immune profile in leptin-deficient mice, Ob/Ob mice were treated by daily injections of GC for 8 weeks and followed for various metabolic and immunological parameters. Marked amelioration of the metabolic alterations characteristic of leptin-deficient mice was observed in GC-treated animals compared with controls. A significant decrease in liver size and hepatic fat content were observed in GC-treated mice. Near-normalization of glucose tolerance and decreased serum triglyceride levels were observed. Fluorescence-activated cell sorting analysis of peripheral and intrahepatic lymphocytes revealed a 1.6-fold increase of the peripheral/intrahepatic NKT lymphocyte ratio. A 33% decrease of serum interferon-gamma level and a 2.6-fold increase of serum interleukin 10 level were noted in GC-treated mice. Immune modulation by GC may have a role in the treatment of nonalcoholic steatohepatitis and other immune-mediated disorders.

Details

Language :
English
ISSN :
00223565 and 15210103
Volume :
319
Issue :
1
Database :
Supplemental Index
Journal :
The Journal of Pharmacology and Experimental Therapeutics
Publication Type :
Periodical
Accession number :
ejs10080888
Full Text :
https://doi.org/10.1124/jpet.106.104950